The global wearable injectors market is projected to reach USD 9.41 billion by 2023 from USD 5.57 billion in 2018, at a CAGR of 11.1%.

Growth in the wearable injectors market is attributed to the increasing prevalence of chronic diseases, favorable reimbursement scenario in major markets, and technological advancements in injector devices.

However, the preference for alternative drug delivery modes and a poor reimbursement structure in developing countries are expected to limit the adoption of wearable injector devices to a certain extent.

The wearable injectors market has been segmented on the basis of type, therapy, and region.

Download FREE Brochure @ https://www.marketsandmarkets.com/pdfdownload.asp?id=100771004

 On the basis of type, the market is segmented into on-body and off-body wearable injectors. The on-body wearable injectors segment is expected to account for the larger market share, while the off-body wearable injectors segment is expected to register the highest CAGR during the forecast period. The drawbacks associated with on-body wearable injectors, such as painful removal, skin sensitivity issues and irritation, and adhesive fitting issues have resulted in the increased adoption of off-body injectors.

On the basis of therapy, the wearable injectors market is segmented into immuno-oncology, diabetes, cardiovascular diseases, and other therapies (Parkinson’s disease, thalassemia, and primary immunodeficiency disorders). The immune-oncology segment is expected to account for the largest market share in 2018, owing to the high prevalence of cancer across the globe.

Geographically, North America dominates the global wearable injectors market in 2018, and this trend is expected to continue during the forecast period. The large share of the North American wearable injectors market is attributed to the rising prevalence of chronic diseases, favorable reimbursement scenario and government support, and presence of major market players in the region.